Quantum Cyber N.V. (QUCY) vs RenovoRx (RNXT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
RenovoRx (RNXT) has outperformed Quantum Cyber N.V. (QUCY) over the past year, gaining 18.3% versus a loss of 48.7%. Over five years, RNXT leads with a -85.3% price change compared with -94.8% for QUCY. RenovoRx is the larger company by market cap ($45.5 million vs $44.7 million), about 1.0 times the size.
RenovoRx converts more of its revenue into profit, with a net margin of -994.5% versus -3018.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QUCY | RNXT |
|---|---|---|
| Share price | $0.512 | $0.942 |
| Market cap | $44.67M | $45.45M |
| 1-day change | -7.25% | -10.29% |
| YTD return | -54.29% | +12.14% |
| 1-year return | -48.75% | +18.34% |
| 5-year return | -94.80% | -85.26% |
| EPS (TTM) | $-2.27 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $537.08K | $1.12M |
| Revenue growth (YoY) | -39.92% | +2511.63% |
| Net income (latest FY) | $-16.21M | $-11.17M |
| Gross margin | 72.58% | 70.88% |
| Operating margin | -3004.97% | -1113.98% |
| Net margin | -3018.31% | -994.48% |
| 52-week high | $4.93 | $2.59 |
| 52-week low | $0.30 | $0.77 |
| Distance from 52-week high | -89.61% | -63.63% |
| Analyst consensus | none | none |
| Avg. price target upside | +1657.81% | +656.90% |
| Average volume | 528.02K | 815.75K |
| Shares outstanding | 87.24M | 48.25M |
| Employees | 10 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNXT has outperformed QUCY by 67.1 percentage points over the past year.
- RenovoRx is more profitable, keeping -994.5 cents of every revenue dollar as net income versus -3018.3 cents for Quantum Cyber N.V..
- RenovoRx grew revenue faster in its latest fiscal year (+2511.63% vs -39.92%).
About Quantum Cyber N.V.
QUCY stock →Quantum Cyber N.V. operates as a technology company focused on cybersecurity and quantum computing solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About RenovoRx
RNXT stock →RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
QUCY vs RNXT FAQ
Which is bigger, Quantum Cyber N.V. or RenovoRx?
RenovoRx (RNXT) is larger, with a market capitalization of $45.45M compared with $44.67M for Quantum Cyber N.V. (QUCY).
Which stock has performed better over the past year, QUCY or RNXT?
RNXT returned +18.34% over the past 12 months, compared with -48.75% for QUCY (price return, excluding dividends). Past performance does not predict future results.
Are Quantum Cyber N.V. and RenovoRx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.